- Trial phase
- Approved (in-hospital); sNDA under FDA review for at-home use
- Time to market
- Already approved as IGALMI for in-hospital use. The at-home label expansion decision is due by November 14, 2026 PDUFA date. If approved, commercial launch for at-home use would follow shortly after, led by Teva.
- Why 5/10
- The next hard, dated catalyst is the FDA PDUFA decision on November 14, 2026 (11 days from today) for the sNDA expanding IGALMI/BXCL501 to at-home use for acute agitation. This is a near-term binary event, but BXCL501 is one of many assets at Teva, a $16B+ revenue diversified pharma company, so even a positive decision would not be a make-or-break event for the stock.
The PDUFA decision on November 14, 2026 is the key catalyst. An approval would validate Teva's $57.5M acquisition and open a first-to-market at-home agitation market. A CRL would be a setback but not devastating for Teva given its diversified portfolio. Watch for any FDA AdComm announcement or pre-PDUFA news flow in the coming days.
Price Chart
Executive Summary
BXCL-501 (dexmedetomidine sublingual film, marketed as IGALMI) is an already FDA-approved drug for acute agitation associated with schizophrenia or bipolar disorder in supervised healthcare settings. Teva acquired worldwide rights from bankrupt BioXcel Therapeutics on October 27, 2026 for $57.5M upfront plus up to $67.5M in milestones. The key near-term catalyst is the November 14, 2026 PDUFA date for a supplemental NDA seeking to expand the label to at-home (outpatient) use, which would make it the first FDA-approved at-home treatment for acute agitation. The addressable market is estimated at up to 86 million annual agitation episodes in the US. Teva is a large, diversified pharma company, so this single drug is a modest pipeline addition rather than a binary bet.
How It Works
BXCL-501 is a sublingual (under-the-tongue) dissolving film containing dexmedetomidine, a drug that activates alpha-2 adrenergic receptors in the brain. This produces a calming effect by reducing the release of norepinephrine, helping to rapidly quiet agitation without heavy sedation. It is absorbed through the oral mucosa in 5-20 minutes.
Trial Status
IGALMI (dexmedetomidine sublingual film) was FDA-approved in April 2022 for acute treatment of agitation associated with schizophrenia or bipolar I/II disorder in adults under healthcare provider supervision. A supplemental NDA (sNDA) was accepted by the FDA in April 2026 seeking label expansion to at-home (outpatient) use, supported by the Phase 3 SERENITY At-Home trial which met its primary safety endpoint across 2,628 agitation episodes with no drug-related serious adverse events. The FDA granted Fast Track designation for agitation in schizophrenia/bipolar/dementia and Breakthrough Therapy designation for agitation in dementia.
The Two-Sided Case
Upcoming Catalysts
- PDUFA target action date of November 14, 2026 for sNDA seeking at-home (outpatient) use label expansion
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Teva Pharmaceutical Industries Ltd PRESS-RELEASE TEVA ·Originating report